{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:13:08Z","timestamp":1771027988460,"version":"3.50.1"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Malignant struma ovarii (MSO) is a rare malignant ovarian tumor, histologically identical to differentiated thyroid cancers. Given the rarity of this disease, there are no treatment guidelines, and the place of imaging for response assessment remains controversial. We report a metabolic response assessed by <jats:sup>18<\/jats:sup>F-FDG PET\/CT in a 71-year-old woman with radioiodine-refractory metastatic MSO treated by targeted therapies (first line with lenvatinib and second line with pazopanib). This case of exceptional response also highlights the usefulness of <jats:sup>18<\/jats:sup>F-FDG PET\/CT for therapeutic assessment of targeted drugs in such a rare clinical entity of malignant MSO.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003374","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T20:00:20Z","timestamp":1605211220000},"page":"52-54","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic Response by 18F-FDG PET\/CT in Metastatic Malignant Struma Ovarii Treated With Targeted Therapies"],"prefix":"10.1097","volume":"46","author":[{"given":"Romain-David","family":"Seban","sequence":"first","affiliation":[{"name":"Nuclear Medicine and Endocrine Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Bozec","sequence":"additional","affiliation":[{"name":"Medical Oncology, Institut Curie, Saint-Cloud, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Nascimento-Leite","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Endocrine Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Champion","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Endocrine Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00404-019-05329-z","article-title":"Struma ovarii with atypical features and synchronous primary thyroid cancer: a case report and review of the literature","volume":"300","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/RLU.0000000000002332","article-title":"Complete remission after single radioiodine therapy in malignant struma ovarii with bone and lymph node metastases","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/01.rlu.0000187497.46941.f6","article-title":"Malignant struma ovarii with peritoneal implants and pelvic structures and liver metastases demonstrated by I-131 SPECT and low-dose CT","volume":"30","year":"2005","journal-title":"Clin Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2967\/jnmt.114.149294","article-title":"Late manifestation of struma peritonei and widespread functioning lesions in the setting of struma ovarii simulating highly differentiated follicular carcinoma","volume":"43","year":"2015","journal-title":"J Nucl Med Technol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12022-015-9394-3","article-title":"Novel BRAF and KRAS mutations in papillary thyroid carcinoma arising in struma ovarii","volume":"26","year":"2015","journal-title":"Endocr Pathol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","article-title":"2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","year":"2019","journal-title":"Eur Thyroid J"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","article-title":"Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study","volume":"11","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:06:08Z","timestamp":1750539968000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003374","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}